Copy to clipboard 
CONMED reported 1Q25 orthopedic sales of $138.3 million, up 2.5% compared to the first quarter of 2024.
The company’s supply chain improvement initiative has three focus areas: procurement and relationships with supply partners, better production planning and production itself. CONMED said it made early progress in the first quarter, reducing the number of SKUs on backorder, but isn’t where it needs to be.
On the bright side, however, the company drove double-digit growth in its foot and ankle offering while also generating strong demand for BioBrace.
There was also some good news, if such a phrase may be used, on CONMED’s exposure to tariffs. The company’s plant in Mexico will be exempt and China is likely to exempt medical devices entering its borders. However, exposure to the high tariff rates in China will increase in 2026.
“It has become clear that product coming from our plant in Mexico will be exempt from tariffs as we are USMCA compliant,” said CONMED CFO Todd Garner. “Our disclosure today is based on a 145% tariff on products coming from China, 25% from Canada and 10% on products from Europe and the rest of the world. Using those percentages, we estimate approximately $5.5 million of supply chain exposure in 2025. 85% of that is from China, 12% is from Europe.”
For the full year, CONMED expects total revenues between $1,350 million and $1,378 million, representing growth between 3.3% and 5.4%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $13.3 | $11.9 | $1.3 | 11% |
| Sports Medicine | $125.0 | $123.0 | $2.0 | 1.7% |
| Total | $138.3 | $134.9 | $3.3 | 2.5% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $52.5 | $54.2 | ($1.6) | (3%) |
| OUS | $85.7 | $80.8 | $5.0 | 6.1% |
| EMEA | $35.9 | $33.2 | $2.7 | 8.3% |
| APAC | $27.0 | $26.2 | $0.7 | 2.8% |
| ROW | $22.8 | $21.3 | $1.5 | 7% |
| Total | $138.3 | $134.9 | $3.3 | 2.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $321.3 | |
| Cost of Sales | $143.5 | 44.7% |
| Selling and Admin | $148.8 | 46.3% |
| R&D | $12.9 | 4% |
| R&D | $12.9 | 4% |
| Other | $9.9 | 3.1% |
| Net Earnings | $6.0 | 1.9% |
CONMED reported 1Q25 orthopedic sales of $138.3 million, up 2.5% compared to the first quarter of 2024.
The company's supply chain improvement initiative has three focus areas: procurement and relationships with supply partners, better production planning and production itself. CONMED said it made early progress in the first quarter,...
CONMED reported 1Q25 orthopedic sales of $138.3 million, up 2.5% compared to the first quarter of 2024.
The company’s supply chain improvement initiative has three focus areas: procurement and relationships with supply partners, better production planning and production itself. CONMED said it made early progress in the first quarter, reducing the number of SKUs on backorder, but isn’t where it needs to be.
On the bright side, however, the company drove double-digit growth in its foot and ankle offering while also generating strong demand for BioBrace.
There was also some good news, if such a phrase may be used, on CONMED’s exposure to tariffs. The company’s plant in Mexico will be exempt and China is likely to exempt medical devices entering its borders. However, exposure to the high tariff rates in China will increase in 2026.
“It has become clear that product coming from our plant in Mexico will be exempt from tariffs as we are USMCA compliant,” said CONMED CFO Todd Garner. “Our disclosure today is based on a 145% tariff on products coming from China, 25% from Canada and 10% on products from Europe and the rest of the world. Using those percentages, we estimate approximately $5.5 million of supply chain exposure in 2025. 85% of that is from China, 12% is from Europe.”
For the full year, CONMED expects total revenues between $1,350 million and $1,378 million, representing growth between 3.3% and 5.4%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $13.3 | $11.9 | $1.3 | 11% |
| Sports Medicine | $125.0 | $123.0 | $2.0 | 1.7% |
| Total | $138.3 | $134.9 | $3.3 | 2.5% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $52.5 | $54.2 | ($1.6) | (3%) |
| OUS | $85.7 | $80.8 | $5.0 | 6.1% |
| EMEA | $35.9 | $33.2 | $2.7 | 8.3% |
| APAC | $27.0 | $26.2 | $0.7 | 2.8% |
| ROW | $22.8 | $21.3 | $1.5 | 7% |
| Total | $138.3 | $134.9 | $3.3 | 2.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $321.3 | |
| Cost of Sales | $143.5 | 44.7% |
| Selling and Admin | $148.8 | 46.3% |
| R&D | $12.9 | 4% |
| R&D | $12.9 | 4% |
| Other | $9.9 | 3.1% |
| Net Earnings | $6.0 | 1.9% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
